217808-43-0

Basic information

• Product Name: rac 4-Amino Deprenyl
• Synonyms: rac 4-Amino Deprenyl;4-AMino-N,α-diMethyl-N-2-propyn-1-ylbenzeneethanaMine
• CAS NO: 217808-43-0
• Molecular Formula: C13H18N2
• Molecular Weight: 202.29542
• Product Categories: Aromatics;Drug Analogues;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 217808-43-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 334.9±27.0 °C(Predicted)
• Appearance: /
• Density: 1.057g/cm³
• Refractive Index: 1.602
• PKA: 7.39±0.50(Predicted)
• CAS DataBase Reference: rac 4-Amino Deprenyl(CAS DataBase Reference)
• NIST Chemistry Reference: rac 4-Amino Deprenyl(217808-43-0)
• EPA Substance Registry System: rac 4-Amino Deprenyl(217808-43-0)

Safety Data

• Hazardous Substances Data: 217808-43-0(Hazardous Substances Data)

Usage

Uses

A structural analog of Deprenyl.

InChI:InChI=1/C13H18N2/c1-3-15(4-2)10-12-9-11-7-5-6-8-13(11)14-12/h5-9,14H,3-4,10H2,1-2H3/i10+1

Upstream product

• 62044-15-9 1-(4-amino-phenyl)propan-2-one 
• 5332-96-7 1-(4-nitrophenyl)propan-2-one 
• 104-03-0 4-nitrobenzeneacetic acid 

Relevant articles and documents

Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease

A series of compounds with monoamine oxidase inhibition and biometal chelation activities were designed, synthesised and evaluated as agents against Alzheimer's disease. The in vitro assay shows that most target compounds exhibit good MAO-B activities with submicromolar IC50 values and antioxidant activity (1.49-5.67 ORAC-FL values). The selected compounds were used to determine the biometal chelating ability using UV-vis spectrometry and high-resolution mass spectrometry, which confirm that they can effectively interact with copper(II), iron(II) and zinc(II). The ThT fluorescence binding assay indicates that the synthetic compounds can inhibit Cu(II)-induced Aβ1-42 aggregation. The parallel artificial membrane permeation assay shows that most target compounds can cross the BBB. Based on these results, compound 8a was selected as a potential multifunctional agent for the treatment of AD.